Evrysdi (risdiplam), marketed by Genentech, a member of the Roche Group, is an FDA-approved therapy to treat SMA. It is an SMN-enhancing therapy that works by targeting the SMN2 gene. It is a small molecule that causes that gene to make more complete SMN protein.

More About Evrysdi

  • As of June 1, 2022 the FDA has extended its approval of Evrysdi (Risdiplam) to treat infants with SMA younger than 2 months old.

  • Evrysdi was tested in a number of different groups, from infants to adults. It is also being studied in individuals who have previously received a different SMN-enhancing therapy. Individuals in this trial must first go through a “washout” period—that is, they must stop taking the previous medication and wait for it to leave the body—before enrolling.
  • Evrysdi is a daily oral medication. It can also be given through a g-tube.
  • Evrysdi must be taken for the duration of the individual’s life.
  • A number of providers are prescribing Evrysdi. You can search some of them on our map locator tool.

  • To find insurance policies and payer information for Evrysdi, please click here.

  • Check out Genentech’s patient brochure on Evrysdi.

  • For the most up-to-date prescribing information, click this link.

Genentech, a member of the Roche Group, logo

History of Evrysdi

Evrysdi is an oral medicine that is systemically distributed and designed to increase SMN protein levels in the central nervous system (CNS) and throughout the body. It is designed to help the SMN2 gene produce more functional SMN protein, which better supports motor neurons and muscle function. Roche and Genentech led the clinical development of Evrysdi in collaboration with The SMA Foundation and PTC Therapeutics. The approval of Evrysdi was based on four multicenter clinical trials in people with SMA.

Roche logo
Genentech, a member of the Roche Group, logo

Recently Shared News on Evrysdi